Bayer stock gains analyst support with upside to consensus targets

Published on 09/19/2026 at 12:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock closed at EUR 48.09 on Xetra on September 18, 2026, with analysts’ average target price at EUR 58.22 implying more than 21 percent upside. The shares carry an OUTPERFORM consensus from 18 analysts, with recent Buy ratings from Deutsche Bank and Barclays.

Flatlay auf weißem Untergrund: weiße runde Tabletten, Marmorstößel, grünes Pflanzenblatt, Glasflakon und gedrucktes DNA-Doppelhelix-Diagramm; Beschriftungskarte mit Text PHARMA — Top-down-Arrangement: weiße Tabletten, Mörser, grünes Blatt, DNA-Diagramm, Beschriftungskarte PHARMA, Illustration mit AI erstellt.

Bayer AG stock (ISIN DE000BAY0017) closed at EUR 48.09 on Xetra on September 18, 2026, with the current consensus average target price of EUR 58.22 pointing to 21.07% upside for investors.

Analysts see upside for Bayer stock

According to MarketScreener on September 18, 2026, Bayer carries a mean analyst consensus rating of OUTPERFORM based on coverage from 18 analysts, with an average target price of EUR 58.22 compared with the last close at EUR 48.09.

As MarketScreener reports, Deutsche Bank Research kept Bayer at Buy on September 10, 2026, with a price target of EUR 60, while Barclays raised its target to EUR 70 and rates the shares Overweight as of September 8, 2026.

The current spread between the average target of EUR 58.22 and the last close of EUR 48.09 implies upside of 21.07%, while the highest published target of EUR 70 reflects potential upside of 45.56% from the same reference price, according to MarketScreener.

Recent ratings underpin sentiment

Analyst activity in early September has been supportive for Bayer stock, with several houses reiterating positive views and adjusting targets upwards. According to MarketScreener, UBS maintained a Buy rating on Bayer on September 1, 2026, while JPMorgan and Goldman Sachs also keep the stock on Buy and have raised their price targets during August.

In this context, Deutsche Bank’s EUR 60 target, Barclays’ EUR 70 target and UBS’s target of EUR 62 all sit above the current Xetra level of EUR 48.09, illustrating that the core analyst group expects further share-price recovery, as reported by MarketScreener.

For retail investors, the key point is the quantified gap between market price and analyst expectations: compared with the lowest target of EUR 46, the shares are just above that floor, whereas relative to the highest target of EUR 70 they still trade more than EUR 20 below, highlighting both perceived upside and the range of views in the analyst community based on data from MarketScreener.

Stock level and valuation snapshot

On the home market Xetra, Bayer’s last close of EUR 48.09 on September 18, 2026, represents a modest year-to-date gain of 29.94% and a five-day change of minus 1.94%, according to the consensus overview on MarketScreener.

The same data set indicates that the stock is also only slightly below the opening level for the year, with a change since January 1 of minus 0.17%, which contrasts with the positive 29.94% performance number quoted for a longer reference period in 2026 in the Xetra snapshot on MarketScreener.

In the United States, Bayer trades as an over-the-counter ADR under the ticker BAYRY. The ADR recently showed a previous close of USD 5.79, a day’s range of USD 5.82 to USD 5.84 and a 52-week range of USD 4.79 to USD 8.58, with an intraday market capitalization indication of around USD 22.95 billion as of the latest data snapshot on Yahoo Finance.

Fundamental backdrop and leverage

While this week’s news flow around Bayer stock is dominated by analyst target updates and consensus data, the fundamental backdrop is shaped by the company’s trailing financials. According to the key statistics section for BAYRY on Yahoo Finance, Bayer generated trailing twelve-month revenue of USD 46.74 billion, with net income attributable to common shareholders of negative USD 880 million and a resulting profit margin of negative 1.88%.

The same overview shows diluted EPS of negative USD 0.23 for the trailing period and a levered free cash flow of USD 5.47 billion, highlighting that despite loss-making headline earnings Bayer is still producing significant cash flow from operations, per data compiled by Yahoo Finance.

On the balance sheet side, Bayer reported total cash of USD 6.34 billion and a total debt to equity ratio of 134.10%, underlining that deleveraging remains a strategic focus for the group as noted in previous analyst commentary and reflected in the leverage figures on Yahoo Finance.

Closing price context for Bayer stock

As of September 18, 2026, Bayer stock trades at EUR 48.09 on Xetra as the primary listing, which is well below the highest published analyst target of EUR 70 but slightly above the lowest target of EUR 46, giving investors a quantified sense of both downside and upside boundaries based on current consensus.